<font color="red">Spotty_1</font> <font color="red">calcification_1</font> as a marker of accelerated progression of coronary atherosclerosis : insights from serial intravascular ultrasound . 
<br>
<br> OBJECTIVES The purpose of this study was to determine atheroma progression in <font color="red">patients_2</font> <font color="red">with_2</font> <font color="red">spotty_2</font> <font color="red">calcification_2</font> <font color="red">._2</font> 
<br> BACKGROUND Although extensively calcified atherosclerotic lesions have been proposed to be clinically quiescent , the presence of spotty calcification within plaque has been reported to be associated with an increased incidence of ischemic cardiovascular events . The relationship between spotty calcification and disease progression has not been investigated . 
<br> METHODS <font color="red">A_1</font> <font color="red">total_1</font> <font color="red">of_1</font> <font color="red">1,347_2</font> <font color="red">stable_2</font> <font color="red">patients_2</font> <font color="red">with_2</font> <font color="red">angiographic_2</font> <font color="red">coronary_2</font> <font color="red">artery_2</font> <font color="red">disease_2</font> underwent serial evaluation of atheroma burden with intravascular ultrasound imaging . <font color="red">Patients_2</font> <font color="red">with_2</font> <font color="red">spotty_2</font> <font color="red">calcification_2</font> <font color="red">were_2</font> <font color="red">identified_2</font> <font color="red">based_2</font> <font color="red">on_2</font> <font color="red">the_2</font> <font color="red">presence_2</font> <font color="red">of_2</font> <font color="red">lesions_2</font> <font color="red">(_2</font> <font color="red">1_2</font> <font color="red">to_2</font> <font color="red">4_2</font> <font color="red">mm_2</font> <font color="red">in_2</font> <font color="red">length_2</font> <font color="red">)_2</font> <font color="red">containing_2</font> <font color="red">an_2</font> <font color="red">arc_2</font> <font color="red">of_2</font> <font color="red">calcification_2</font> <font color="red">of_2</font> <font color="red"><_2</font> <font color="red">90°._2</font> Clinical characteristics and disease progression were compared between <font color="red">patients_1</font> <font color="red">with_1</font> <font color="red">spotty_1</font> <font color="red">calcification_1</font> <font color="red">(_1</font> <font color="red">n_1</font> <font color="red">=_1</font> <font color="red">922_1</font> <font color="red">)_1</font> and those with no calcification ( n = 425 ) . 
<br> RESULTS <font color="red">Patients_1</font> <font color="red">with_1</font> <font color="red">spotty_1</font> <font color="red">calcification_1</font> were older ( age 56 years vs. 54 years ; p = 0.001 ) , more likely to be male ( 68% vs. 54% ; p = 0.01 ) , and have a history of diabetes mellitus ( 30% vs. 24% ; p = 0.01 ) and myocardial infarction ( 28% vs. 20% ; p = 0.004 ) , and have lower on - treatment high - density lipoprotein cholesterol levels ( 48 ± 16 mg / dl vs. 51 ± 17 mg / dl ; p = 0.001 ) . <font color="red">Patients_1</font> <font color="red">with_1</font> <font color="red">spotty_1</font> <font color="red">calcification_1</font> demonstrated a greater percent atheroma volume ( PAV ) ( 36.0 ± 7.6% vs. 29.0 ± 8.5% ; p < 0.001 ) and total atheroma volume ( 174.6 ± 71.9 mm(3 ) vs. 133.9 ± 64.9 mm(3 ) ; p < 0.001 ) . On serial evaluation , spotty calcification was associated with greater progression of PAV ( + 0.43 ± 0.07% vs. + 0.02 ± 0.11% ; p = 0.002 ) . Although intensive low - density lipoprotein cholesterol and blood pressure lowering therapy slowed disease progression , these efficacies were attenuated in <font color="red">patients_1</font> <font color="red">with_1</font> <font color="red">spotty_1</font> <font color="red">calcification_1</font> <font color="red">._1</font> <font color="red">
<br>_1</font> CONCLUSIONS The presence of <font color="red">spotty_1</font> <font color="red">calcification_1</font> is associated with more extensive and diffuse coronary atherosclerosis and accelerated disease progression despite use of medical therapies .